These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9402044)

  • 21. Neuropeptide Y-mediated constriction and dilation in rat middle cerebral arteries.
    You J; Edvinsson L; Bryan RM
    J Cereb Blood Flow Metab; 2001 Jan; 21(1):77-84. PubMed ID: 11149671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vascular pharmacology of BIIE0246, the first selective non-peptide neuropeptide Y Y(2) receptor antagonist, in vivo.
    Malmström RE
    Br J Pharmacol; 2001 Aug; 133(7):1073-80. PubMed ID: 11487518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BIBP3226 inhibits neuropeptide Y and pancreatic polypeptide potentiated neurogenic vasoconstriction.
    Barrios VE; Nelson AG; Toombs CF
    Life Sci; 1998; 62(6):525-32. PubMed ID: 9464464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal and cardiovascular role of the neuropeptide Y Y1 receptor in ischaemic heart failure rats.
    Zhao XH; Sun XY; Bergdahl A; Edvinsson L; Hedner T
    J Pharm Pharmacol; 1999 Nov; 51(11):1257-65. PubMed ID: 10632083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of noradrenaline and neuropeptide Y on rat mesenteric microvessel contraction.
    Chen H; Fetscher C; Schäfers RF; Wambach G; Philipp T; Michel MC
    Naunyn Schmiedebergs Arch Pharmacol; 1996 Feb; 353(3):314-23. PubMed ID: 8692287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
    Wieland HA; Willim KD; Entzeroth M; Wienen W; Rudolf K; Eberlein W; Engel W; Doods HN
    J Pharmacol Exp Ther; 1995 Oct; 275(1):143-9. PubMed ID: 7562543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuropeptide Y and mesenteric sympathetic vasoconstriction in pregnant and non-pregnant Wistar-Kyoto rats.
    Chu ZM; Beilin LJ
    Clin Exp Pharmacol Physiol; 1998; 25(7-8):630-2. PubMed ID: 9673442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuropeptide Y Y1 receptor mechanisms in sympathetic vascular control.
    Malmström RE
    Acta Physiol Scand Suppl; 1997; 636():1-55. PubMed ID: 9179320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dissociation of potentiation of Leu31 Pro34 neuropeptide Y on adrenergic and purinergic transmission in isolated canine splenic artery.
    Yang XP; Chiba S
    Jpn J Pharmacol; 2000 Jul; 83(3):197-205. PubMed ID: 10952068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional interaction between neuropeptide Y receptors and modulation of calcium channels in the rat hippocampus.
    Silva AP; Carvalho AP; Carvalho CM; Malva JO
    Neuropharmacology; 2003 Feb; 44(2):282-92. PubMed ID: 12623227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of effect of a selective vasopressin V1A receptor antagonist SR 49,059, on potentiation by vasopressin of adrenoceptor-mediated pressor responses in the rat mesenteric arterial bed.
    Heinemann A; Horina G; Stauber RE; Pertl C; Holzer P; Peskar BA
    Br J Pharmacol; 1998 Nov; 125(6):1120-7. PubMed ID: 9863637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stimulation of the sympathetic perimesenteric arterial nerves releases neuropeptide Y potentiating the vasomotor activity of noradrenaline: involvement of neuropeptide Y-Y1 receptors.
    Donoso MV; Brown N; Carrasco C; Cortes V; Fournier A; Huidobro-Toro JP
    J Neurochem; 1997 Sep; 69(3):1048-59. PubMed ID: 9282927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Possible involvement of neuropeptide Y Y1 receptors in antidepressant like effect of agmatine in rats.
    Kotagale NR; Paliwal NP; Aglawe MM; Umekar MJ; Taksande BG
    Peptides; 2013 Sep; 47():7-11. PubMed ID: 23816796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Separate modulation of neuropeptide Y1 receptor on purinergic and on adrenergic neuroeffector transmission in canine splenic artery.
    Yang XP; Chiba S
    J Cardiovasc Pharmacol; 2001 Oct; 38 Suppl 1():S17-20. PubMed ID: 11811353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuropeptide Y1 receptor vasoconstriction in exercising canine skeletal muscles.
    Buckwalter JB; Hamann JJ; Clifford PS
    J Appl Physiol (1985); 2005 Dec; 99(6):2115-20. PubMed ID: 16099895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence for involvement of neuropeptide Y receptors in the regulation of food intake: studies with Y1-selective antagonist BIBP3226.
    Kask A; Rägo L; Harro J
    Br J Pharmacol; 1998 Aug; 124(7):1507-15. PubMed ID: 9723965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of neuropeptide Y and agonists selective for neuropeptide Y receptor sub-types on arterioles of the guinea-pig small intestine and the rat brain.
    Xia J; Neild TO; Kotecha N
    Br J Pharmacol; 1992 Nov; 107(3):771-6. PubMed ID: 1472974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuropeptide Y lowers blood glucose in anaesthetized rats via a Y5 receptor subtype.
    Bischoff A; Michel MC
    Endocrinology; 1998 Jun; 139(6):3018-21. PubMed ID: 9607814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of NPY receptors mediating contraction in rat intramyocardial coronary arteries.
    Prieto D; García-Sacristán A; Simonsen U
    Regul Pept; 1998 Sep; 75-76():155-60. PubMed ID: 9802404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
    Sautel M; Rudolf K; Wittneben H; Herzog H; Martinez R; Munoz M; Eberlein W; Engel W; Walker P; Beck-Sickinger AG
    Mol Pharmacol; 1996 Aug; 50(2):285-92. PubMed ID: 8700135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.